一、本人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、部门规章及其他规范性文件，具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求： 科创板上市公司独立董事候选人声明与承诺 本人吴向阳，已充分了解并同意由提名人上海凯赛生物技术 股份有限公司董事会提名为上海凯赛生物技术股份有限公司第 三届董事会独立董事候选人。本人公开声明，本人具备独立董事 任职资格，保证不存在任何影响本人担任上海凯赛生物技术股份 有限公司独立董事独立性的关系，具体声明并承诺如下： （一）《中华人民共和国公司法》等关于董事任职资格的规 定； （二）中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定； （三）其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、本人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其直系亲属 和主要社会关系（直系亲属是指配偶、父母、子女等；主要社会 关系是指兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟 姐妹、子女的 ...

提名人上海凯赛生物技术股份有限公司董事会，现提名商建 刚先生为上海凯赛生物技术股份有限公司第三届董事会独立董 事候选人，并已充分了解被提名人职业、学历、职称、详细的工 作经历、全部兼职、有无重大失信等不良记录等情况。被提名人 已书面同意出任上海凯赛生物技术股份有限公司第三届董事会 独立董事候选人（参见该独立董事候选人声明）。提名人认为， 被提名人具备独立董事任职资格，与上海凯赛生物技术股份有限 公司之间不存在任何影响其独立性的关系，具体声明并承诺如下： 科创板上市公司独立董事提名人声明与承诺 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 （三）其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、被提名人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其直系亲属 和主要社会关系（直系亲属是指配偶、父母、子女等；主要社会 关系是指兄弟姐妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟 姐妹、子女 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-039 上海凯赛生物技术股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 18 日 至2025 年 8 月 18 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年8月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-1 ...

格隆汇8月1日丨凯赛生物(688065.SH)公布，2025年7月31日，公司通过上海证券交易所交易系统以集中 竞价交易方式回购公司股份230,366股,占公司总股本721,289,794股的比例为0.0319%。回购成交的最高 价为53.40元/股，最低价为44.08元/股，支付的资金总额为人民币10,497,716.71元（不含印花税、交易佣 金等交易费用)。 ...

凯赛生物7月31日报收48.10元，较前一交易日下跌2.1%。盘中最高触及49.12元，最低下探47.90元，成 交金额1.56亿元。 7月31日主力资金净流入904.16万元，占流通市值比例为0.03%。从资金流向来看，当日呈现资金净流入 状态。 风险提示：市场有风险，投资需谨慎。 该公司属于化学制品行业，主营业务为生物基材料的研发、生产和销售。作为科创板上市公司，凯赛生 物专注于合成生物学领域的技术创新和产业化应用。 公开信息显示，凯赛生物今年已完成59亿元规模的定向增发，募集资金全部用于补充流动资金和偿还银 行贷款。此次定增规模超过公司IPO融资金额，在年内A股市场40亿元以上规模的定增案例中位居前 列。 ...

Core Viewpoint - The Ministry of Industry and Information Technology of China has officially announced the first batch of "Biomanufacturing Iconic Products," which includes 36 products from various companies, marking a significant step in technological innovation and industrial upgrading in the biomanufacturing sector [1]. Summary by Relevant Sections Biomanufacturing Iconic Products - The list includes 36 companies such as Beijing Shulang Biotechnology, Micro Yuan Synthesis, and Qilu Pharmaceutical, showcasing the diversity and innovation within the biomanufacturing industry [1]. - The products range from biopharmaceuticals to food additives, indicating a broad application of biomanufacturing technologies across different sectors [1]. Notable Products - Ethanol Clostridium protein produced by Beijing Shulang is a feed protein supplement derived from microbial fermentation using industrial waste gases [4]. - Alotose, produced by Micro Yuan Synthesis, is a low-calorie sweetener that enhances production efficiency through microbial fermentation [4]. - Polyhydroxyalkanoate (PHA) from Beijing Microstructure is a biodegradable material that can replace plastics, reducing environmental pollution [4]. - CAR-T cell therapy product, Nakiolun, developed by Huyuan Biotechnology, shows significant advancements in cancer treatment [4]. - Various other products include natural extracts, amino acids, and vaccines, highlighting the innovative approaches in biomanufacturing [4][5][6][7]. Industry Significance - The announcement reflects the government's commitment to promoting the biomanufacturing industry, which is crucial for technological advancement and economic growth [1]. - The diversity of products indicates a growing trend towards sustainable and environmentally friendly manufacturing practices within the industry [1].

Group 1 - The core viewpoint of the article emphasizes the rapid development of China's non-grain bio-based materials industry driven by low-carbon transformation and dual carbon strategies, supported by policies and technological advancements [1][18][23] - In 2023, six departments jointly released the "Three-Year Action Plan for Accelerating the Innovative Development of Non-Grain Bio-Based Materials," outlining key goals for 2025 [1][32] - The industry is transitioning from laboratory-scale to large-scale production, with significant projects like the establishment of a 10,000-ton non-grain bio-based rubber production line and a 100,000-ton PLA production line [1][27][23] Group 2 - The non-grain bio-based materials industry is characterized by its use of non-food biomass, which avoids competition with food production and offers sustainable, biodegradable alternatives to traditional petroleum-based materials [7][9][18] - The industry is expected to replace over 30% of grain-based products by 2030, driven by continuous policy support and technological advancements [9][10][18] - The industry is currently in a phase of industrialization breakthroughs, with significant advancements in synthetic biology and CO₂ biomanufacturing technologies [1][27][49] Group 3 - The development of non-grain bio-based materials is crucial for achieving resource security, reducing carbon emissions, and promoting sustainable development [18][19] - The industry has a rich resource endowment, with agricultural waste and forestry residues providing a sustainable raw material supply [40][45] - Technological breakthroughs in synthetic biology and process engineering are accelerating the industrialization of non-grain bio-based materials, enhancing their competitiveness against petroleum-based products [49][50][57]

Core Viewpoint - Synthetic biology is an underappreciated industry that has the potential to significantly change manufacturing methods, with Kasei Biotech positioned as a leading player in this field [1] Group 1: Technology Core - Kasei's core technology barriers include autonomous strain construction, industrial fermentation capabilities, and integrated engineering systems, allowing it to develop new materials independently [6][8][10] - The ability to scale from laboratory to industrial production is crucial for transforming research outcomes into marketable products [9] Group 2: Business Model - Kasei's business model focuses on selling products rather than licensing technology, with a strong emphasis on self-research, production, and sales [11] - Key product lines include bio-based pentamethylenediamine and long-chain dicarboxylic acids, which serve as alternatives to petrochemical materials [12][13] - The model emphasizes scalability and cost reduction, with strong customer relationships and high switching costs [14] Group 3: Industry Positioning - Kasei is a global leader in the synthetic biology sector, producing bio-based materials at a scale of tens of thousands of tons [15] - The company has a stable international customer base, with a significant portion of its business coming from exports [16] Group 4: Financial Health - Kasei has achieved consistent profitability, with stable gross margins between 35-45% and a self-sustaining cash flow structure [17][18] - The company maintains a healthy balance sheet with controlled debt levels, indicating a stable expansion strategy [19][24] Group 5: Moat and Long-term Evolution - Kasei's long-term advantages include a technical flywheel effect, strong customer loyalty, and production capacity barriers that are not easily replicated [20] - The company is positioned to evolve from a single product focus to a platform-based industrial biotechnology company [21] Summary of Q1 2025 Financial Performance - Revenue reached 776 million yuan, a year-on-year increase of 13.33%, indicating a recovery in demand for core bio-based materials [21] - Net profit grew by 30.11% to 137 million yuan, reflecting improved profitability and cost control [22] - The company shows strong operational cash flow without reliance on external financing, maintaining a stable financial structure [23][24]

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

Core Points - The company announced a cash dividend of 0.4 yuan per share for the 2024 fiscal year [2][10] - The profit distribution plan was approved at the annual shareholders' meeting held on June 27, 2025 [2][4] - The total cash dividend to be distributed amounts to approximately 287.58 million yuan, based on the adjusted total share capital [4][10] Distribution Plan - The distribution is based on the total share capital of 721,289,794 shares, excluding 2,341,165 shares held in the repurchase account [4][5] - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date [3][4] Implementation Method - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited [8] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [8] Taxation Information - Individual shareholders holding unrestricted shares for over one year will not be subject to personal income tax on the dividends [10][11] - For shares held for less than one year, the tax will be calculated upon transfer of the shares, with specific rates applied based on the holding period [10][11] - For foreign institutional investors, a 10% withholding tax will be applied to the dividends [12][13]